

Financial news for RXDX dated on 2018-01-10: Roche Commences Tender Offer for All Shares of Ignyta for \$27.00/Share in Cash

Financial news for RXDX dated on 2017-12-29: Ignyta Shares Quiet Premarket Following FDA Clearance Of IND For RXDX-106; 5 Insiders Issued Form 4 Filings Late Thurs. Night, Disclosed Sale Of ~42K Shares

Financial news for RXDX dated on 2017-12-29: Ignyta Reports FDA Clearance of IND for RXDX-106

Financial news for RXDX dated on 2017-12-28: Benzinga's Top Upgrades, Downgrades For December 28, 2017

Financial news for RXDX dated on 2017-12-26: Benzinga's Top Upgrades, Downgrades For December 26, 2017

Financial news for RXDX dated on 2017-12-26: Ladenburg Thalmann Downgrades Ignyta to Neutral

Financial news for RXDX dated on 2017-12-26: 44 Biggest Movers From Friday

Financial news for RXDX dated on 2017-12-22: Mid-Afternoon Market Update: Dow Falls Over 50 Points; SMART Global Shares Spike Higher

Financial news for RXDX dated on 2017-12-22: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for RXDX dated on 2017-12-22: Mid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge

Financial news for RXDX dated on 2017-12-22: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for RXDX dated on 2017-12-22: Roche to Acquire Ignyta for \$27.00/Share in Cash

Financial news for RXDX dated on 2017-12-21: Reuters Reports Ignyta In Advanced Talks to Sell Itself

Financial news for RXDX dated on 2017-12-05: Global Mizuho Investor Conference Concludes Today, Presenters Include Ignyta, Novocure and Akebia Therapeutics

Financial news for RXDX dated on 2017-11-29: Piper Jaffray Healthcare Conference Concludes Today, Presenters Include: Kadmon, Ignyta, Eagle Pharmaceuticals, Tandem Diabetes Care, DexCom, and Alnylam Pharmaceuticals

Financial news for RXDX dated on 2017-11-16: Jefferies 2017 London Healthcare Conference Concludes Today, Presenters Include: Ignyta, Heron Therapeutics, and TherapeuticsMD

Financial news for RXDX dated on 2017-11-14: 13F Filing From Baker Bros Shows New Stake In GW Pharmaceuticals, Slight Increase To Ignyta Stake, Exited Stake In Palatin Technologies and Zogenix

Financial news for RXDX dated on 2017-11-08: Credit Suisse Healthcare Conference Concludes Today, Presenters Include: Community Health Systems, Innoviva, Ironwood Pharmaceuticals, Ignyta, Alnylam, and HCA Healthcare

Financial news for RXDX dated on 2017-11-07: Ignyta Reports Q3 EPS \$(0.51) vs. \$(0.54) Est., No Sales

Financial news for RXDX dated on 2017-10-19: 38 Biggest Movers From Yesterday

Financial news for RXDX dated on 2017-10-18: Adam Feuerstein Tweets: \$RXDX \$125M stock offering, so now we have enough examples to fully establish simultaneous data/stock sale strategy as a real (new) thing.

Financial news for RXDX dated on 2017-10-18: UPDATE: Ignyta Issues PR Saying They Commenced A Public Offering Of \$125M Of Stock

Financial news for RXDX dated on 2017-10-18: Ignyta Filing Shows Registration For Mixed Securities Shelf Offering, Amounts Not Disclosed

Financial news for RXDX dated on 2017-10-18: 32 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RXDX dated on 2017-10-18: 4 Biotech & Health Stocks To Watch

Financial news for RXDX dated on 2017-10-18: Analyst: Entrectinib's Potential Gives

Ignyta's Stock 116% Upside

Financial news for RXDX dated on 2017-10-18: Adam Feurestein Tweets: Yes, really. The \$RXDX data today are consistent and positive. I love nitpicking as much next guy but sometimes you can go overboard.

Financial news for RXDX dated on 2017-10-18: Ignyta Shares Tick Higher Off Session Lows, Up 13% For Session As Traders Circulate Price Target Increase From \$20.25 To \$30 From Ladenburg Thalmann

Financial news for RXDX dated on 2017-10-18: Mid-Morning Market Update: Markets Mostly Higher; Abbott Tops Q3 Views

Financial news for RXDX dated on 2017-10-18: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RXDX dated on 2017-10-18: Ignyta +23.69% Premarket @\$17.75 After Co Reports Positive NSC Lung Cancer Data

Financial news for RXDX dated on 2017-10-18: Adam Feuerstein Tweet: Ignyta drug targeting rare lung cancer shows early promise, even when tumors spread to brain statnews.com/2017/10/17/ign... \$RXDX

Financial news for RXDX dated on 2017-10-18: Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive NSCLC

Financial news for RXDX dated on 2017-10-17: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for RXDX dated on 2017-10-17: Ignyta Granted Priority Medicines Designation by the EMA for Entrectinib

Financial news for RXDX dated on 2017-10-16: The Week Ahead: Earnings, Earnings, And More Earnings

Financial news for RXDX dated on 2017-10-02: Ignyta To Highlight New Data On Immuno-Oncological Efficacy Of RXDX-106 At AACR: '...appears to restore and enhance overall immune function...'

Financial news for RXDX dated on 2017-09-27: Cantor Fitzgerald Global Healthcare Conference Concludes Today, Presenters Include: Cerus, Ignyta, and Aerie Pharmaceuticals

Financial news for RXDX dated on 2017-09-15: Seeing Notable Block Trade In Ignyta After-Hours; 1.2M Shares At \$11.65

Financial news for RXDX dated on 2017-09-11: 13G Filing Shows Cormorant Asset Management Reporting 4.4% Stake In Ignyta

Financial news for RXDX dated on 2017-09-06: UPDATE: Ignyta Says 'Entrectinib ROS1 NSCLC data update to be provided at a medical conference in Q4 2017'

Financial news for RXDX dated on 2017-09-06: Ignyta Offers Regulatory Update On Entrectinib ROS1 Lung Cancer Development Program: 'ROS1 program has achieved enrollment of the registration efficacy data set of over 50 patients to support NSCLC NDA submission'

Financial news for RXDX dated on 2017-08-31: 18 Biggest Mid-Day Gainers For Thursday

Financial news for RXDX dated on 2017-08-14: 13F From Farallon Capital Shows New Stakes In Akebia Therapeutics, Amicus Therapeutics, Cabela's, Huntsman, Ignyta, Savara

Financial news for RXDX dated on 2017-08-08: Ignyta Reports Q2 EPS \$(0.56) vs \$(0.61) Est.

Financial news for RXDX dated on 2017-07-17: 4 Sell-Ranked Drug Stocks To Avoid Ahead Of Q2 Earnings

Financial news for RXDX dated on 2017-07-10: A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Consumer Credit Data

Financial news for RXDX dated on 2017-07-10: Ignyta Receives FDA Orphan Drug Designation for Entrectinib

Financial news for RXDX dated on 2017-06-23: 6 Biotech Stocks Jefferies Says Are Undervalued

Financial news for RXDX dated on 2017-06-07: Jefferies Health Care Conference Continues Today, Presenters Include Teva, WAVE Life Sciences, Envision Healthcare, NantKwest, Ignyta, Puma Biotech, and Kite Pharma

Financial news for RXDX dated on 2017-05-15: Ignyta Gets Breakthrough Therapy Designation for Entrectinib by the FDA

Financial news for RXDX dated on 2017-05-04: 20 Biggest Mid-Day Gainers For Thursday

Financial news for RXDX dated on 2017-05-04: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for RXDX dated on 2017-05-04: Ignyta Prices 12.5M Shares at \$6.15/Share

Financial news for RXDX dated on 2017-05-02: Ignyta Announces 1.5M Share Offering Common Stock

Financial news for RXDX dated on 2017-05-01: Ignyta Reports Q1 EPS \$(0.96) vs \$(0.69) Est.

Financial news for RXDX dated on 2017-04-27: Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions

Financial news for RXDX dated on 2017-04-27: Ignyta To Provide Comprehensive Update On Entrectinib Program And STARTRK-2 4:30pm ET Today

Financial news for RXDX dated on 2017-03-30: UPDATE: Ignyta Says 'One patient with an NTRK1 fusion was treated with entrectinib, resulting in 60% tumor regression and resolution of clinical symptoms that was maintained for 11 months on treatment'

Financial news for RXDX dated on 2017-03-30: Ignyta Reports Peer-Reviewed Publication of Activity of TRK Inhibitor in Primary Brain Tumor: 'Study found three NTRK fusions within cohort of 26 glioneuronal tumors'

Financial news for RXDX dated on 2017-03-23: Ignyta Announces Exploration Of Strategic Options For Taladegib, Enabled By New License Agreement With Eli Lilly

Financial news for RXDX dated on 2017-03-14: Ignyta Reports FY16 EPS \$(2.69) vs \$(2.60) Est.

Financial news for RXDX dated on 2016-12-01: Ignyta Announces Promising Efficacy Data in Phase 1/1b Clinical Data on RXDX-105 at 2016 EORTC-NCI-AACR Annual Meeting

Financial news for RXDX dated on 2016-11-29: PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio

Financial news for RXDX dated on 2016-11-17: Jefferies London Health Care Conference Continues Today

Financial news for RXDX dated on 2016-11-07: Ignyta Reports Q3 Loss/Share \$0.56 vs Est Loss/Share \$0.67

Financial news for RXDX dated on 2016-09-19: Ignyta Announces Contract the European Organisation for Research and Treatment of Cancer

Financial news for RXDX dated on 2016-08-31: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for RXDX dated on 2016-08-31: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RXDX dated on 2016-08-31: Ignyta Announces Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the STARTRK-2 Trial

Financial news for RXDX dated on 2016-08-16: Dir Bristol Buys 5,000 Shares Of Ignyta @\$5.65/Share -Form 4

Financial news for RXDX dated on 2016-08-09: Ignyta Reports Q2 EPS \$(0.70) vs. Est. \$(0.65)

Financial news for RXDX dated on 2016-06-30: Ignyta Reports Securing of \$42M Term Loan Facility

Financial news for RXDX dated on 2016-06-23: Ignyta Gets A Bullish Initiation From JPMorgan

Financial news for RXDX dated on 2016-06-23: JP Morgan Initiates Coverage on Ignyta

at Overweight, Announces \$15.00 PT

Financial news for RXDX dated on 2016-06-17: Ignyta's Entrectinib Data May Come By Year's End; Cantor Keeps Buy Rating, But Stock Slips 4%

Financial news for RXDX dated on 2016-06-05: Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at #ASCO16

Financial news for RXDX dated on 2016-05-10: Ignyta Reports Q1 EPS \$(0.79) vs \$(0.68) Est.

Financial news for RXDX dated on 2016-04-29: Ignyta Prices 8M Share Offering @\$6.25/Share

Financial news for RXDX dated on 2016-04-27: Ignyta Shares Indicated Lower Following News of ~\$50M Offering of Shares

Financial news for RXDX dated on 2016-04-20: Ignyta Release Slide Presentation from Webcast

Financial news for RXDX dated on 2016-04-18: Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Q1 Profit Beats Expectations

Financial news for RXDX dated on 2016-04-18: Ignyta Shares Up 13% Premarket; Earlier Release Showed Entrectinib was Well Tolerated in Phase 1 Trial, Showed Tumor Regression Seen in 80% of Patients

Financial news for RXDX dated on 2016-04-18: Ignyta Announces Alexander Drilon, M.D. of Memorial Sloan Kettering Cancer Center, New York, New York, Presented Updated Results from the Phase 1 Clinical Trials of Entrectinib

Financial news for RXDX dated on 2016-03-24: Ignyta Shares Unch Following 13G Filing from Armistice Capital Showing 5.4% Stake

Financial news for RXDX dated on 2016-03-21: Director Fredo Buys 3,000 Shares of Ignyta @\$5.39/Share -Form 4

Financial news for RXDX dated on 2016-03-16: Ignyta Reports Granting of Inducement Award for Option to Purchase 9K Shares of Common Stock at \$5.55/Share

Financial news for RXDX dated on 2016-03-15: Mid-Afternoon Market Update: Celator Pharmaceuticals Surges On Phase 3 Trial Results For Vyxeos; Constellium Shares Slide

Financial news for RXDX dated on 2016-03-15: Credit Suisse Maintains Outperform on Ignyta, Lowers PT to \$17.00

Financial news for RXDX dated on 2016-03-14: Ignyta Reports FY15 EPS \$(3.44) vs. Est. \$(2.49)

Financial news for RXDX dated on 2016-03-10: Ignyta Announces Selection of Recommended Phase 2 Dose and Initiation of Phase 1b Basket Trial of RXDX-105

Financial news for RXDX dated on 2016-02-23: UPDATE: Ignyta Reports Cessation of All Development Activities Related to RXDX-107, -103, -108 Programs, Some Spark Discovery Programs

Financial news for RXDX dated on 2016-02-23: Ignyta Reports Strategic Positioning for Prioritized Pipeline: Renewed Commitment for Core Rx/Dx Business, Continued Activities in Furtherance of Immuno-Oncology, Cancer Stem Cell Programs

Financial news for RXDX dated on 2016-01-20: Credit Suisse Initiates Coverage on Ignyta at Outperform, Announces \$19.00 PT

Financial news for RXDX dated on 2016-01-06: Jefferies' Best Biotech Ideas For 2016 (And Beyond)

Financial news for RXDX dated on 2015-12-23: S-3 from Ignyta Shows Registration for ~2.713M Share Common Stock Offering via Selling Holders

Financial news for RXDX dated on 2015-12-17: CFO Chacko Buys 1,500 Shares of Ignyta @\$12.00/Share -Form 4

Financial news for RXDX dated on 2015-12-08: Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma

Financial news for RXDX dated on 2015-12-07: Ignyta Names William McCarthy as Chief Business Officer

Financial news for RXDX dated on 2015-11-30: Ignyta and EORTC Announce Entrectinib

Selected as First Investigational Cancer Agent to be Included in EORTC SPECTA Precision Medicine Clinical Trial Program

Financial news for RXDX dated on 2015-11-19: Moffitt Cancer Center and Ignyta, Inc. Enter into Cancer Research Collaboration for RXDX-106

Financial news for RXDX dated on 2015-11-09: Ignyta Reports Q3 EPS \$(0.49) vs \$(0.60) Est.

Financial news for RXDX dated on 2015-11-08: Ignyta Announces Positive Interim Data from RXDX-105 Phase 1 Clinical Trial at 2015 EORTC-NCI-AACR Conference

Financial news for RXDX dated on 2015-11-08: Ignyta Acquires Exclusive Rights to Taladegib Oncology Program from Lilly for \$2M, ~1.2M Ignyta Shares

Financial news for RXDX dated on 2015-10-23: Benzinga's Top Initiations

Financial news for RXDX dated on 2015-10-23: Jefferies Initiates Coverage on Ignyta at Buy, Announces \$18.00 PT

Financial news for RXDX dated on 2015-10-06: Ignyta Announces Issuance of Patent Covering Composition of Matter of RXDX-107

Financial news for RXDX dated on 2015-09-30: Ignyta Reports Beginning of STARTRK-2 Phase 2 Clinical Trial of Entrectinib

Financial news for RXDX dated on 2015-09-27: Ignyta Presents Updated Interim Data from Entrectinib Phase 1 Clinical Trials at ECC 2015

Financial news for RXDX dated on 2015-09-21: Ignyta Announces Entrectinib Phase 1 Data Presentation at the 2015 European Cancer Congress

Financial news for RXDX dated on 2015-09-17: Ignyta Reports Initiation of Phase 1/1b Clinical Trial of RXDX-107

Financial news for RXDX dated on 2015-08-10: Ignyta Reports Q2 EPS \$(0.51) vs. Est. \$(0.51)

Financial news for RXDX dated on 2015-07-29: Ignyta Announces FDA Clearance of IND for RXDX-107

Financial news for RXDX dated on 2015-07-06: Ignyta Announces Collaboration with UCSF For Clinical Trial of Entrectinib

Financial news for RXDX dated on 2015-06-30: Ignyta Reports the Release for Clinical Use of a Proprietary NGS Clinical Trial Assay to Support Its STARTRK Clinical Studies

Financial news for RXDX dated on 2015-06-22: Ignyta Shares Gap Down on Volume

Financial news for RXDX dated on 2015-06-22: Benzinga's Top Initiations

Financial news for RXDX dated on 2015-06-22: Piper Jaffray Initiates Ignyta With Overweight

Financial news for RXDX dated on 2015-06-22: Piper Jaffray Initiates Coverage on Ignyta at Overweight, Announces \$34.00 PT

Financial news for RXDX dated on 2015-06-10: Ignyta Prices ~4.28M Share Offering @\$17.50/Share

Financial news for RXDX dated on 2015-06-09: Ignyta Shares Are Up ~1% After Hours Following Announcement Of \$75M Share Offering

Financial news for RXDX dated on 2015-06-09: Ignyta Announces \$75M Common Stock Offering

Financial news for RXDX dated on 2015-06-02: Benzinga's Volume Movers

Financial news for RXDX dated on 2015-06-01: Benzinga's Volume Movers

Financial news for RXDX dated on 2015-06-01: Stocks Hitting 52-Week Highs

Financial news for RXDX dated on 2015-06-01: Morning Market Gainers

Financial news for RXDX dated on 2015-06-01: Ignyta Offers Results from Phase 1 Trial on Entrectinib

Financial news for RXDX dated on 2015-05-19: Ignyta Announces Two Entrectinib Phase I Data Presentations and Webcast Management Presentation at the 2015 ASCO Annual

Meeting

Financial news for RXDX dated on 2015-05-18: 5 Small Caps With CapEx As Much As 20x Revenue

Financial news for RXDX dated on 2015-03-24: 13F Shows IGNYTA Holder Broadfin Reports 6.4% Stake Up From 2.7%

Financial news for RXDX dated on 2015-03-18: Morning Market Gainers

Financial news for RXDX dated on 2015-03-17: 8-K from Ignyta Shows Co. Will Sell ~4.2M in Shares Amid Deal with Teva

Financial news for RXDX dated on 2015-03-17: Ignyta Shares to Resume Trade at 4:30 p.m. EDT

Financial news for RXDX dated on 2015-03-17: UPDATE: Teva Sale of Units to Ignyta Consists of ~1.5M Shares of RXDX Shares

Financial news for RXDX dated on 2015-03-17: Ignyta Shares Halted News Disseminated: Co. Announces Purchase of Four Oncology Units from Teva

Financial news for RXDX dated on 2015-02-05: Ignyta Receives FDA Orphan Drug Designation for Entrectinib

Financial news for RXDX dated on 2015-02-02: Ignyta Names Pratik Multani, M.D., M.S., as CMO

Financial news for RXDX dated on 2014-12-29: Morning Market Movers

Financial news for RXDX dated on 2014-12-29: Monday's #PreMarket Movers: MTW, RXDX, RVLTT Higher; AMBA, SWKS Lower

Financial news for RXDX dated on 2014-12-29: Why Shares of Ignyta Are Trading Higher

Financial news for RXDX dated on 2014-12-29: Benzinga's Top #PreMarket Gainers

Financial news for RXDX dated on 2014-12-29: UPDATE: Ignyta Shares Rise 8% Following Report of FDA Orphan Drug, Rare Pediatric Disease Designations for Entrectinib for Neuroblastoma

Financial news for RXDX dated on 2014-12-29: Ignyta Reports Receiving of Orphan Drug, Rare Pediatric Disease Designations for Entrectinib for Neuroblastoma

Financial news for RXDX dated on 2014-12-15: Ignyta Announces Amendment to License Agreement with Nerviano

Financial news for RXDX dated on 2014-12-09: Ignyta Announces WHO Approval of Nonproprietary Name Entrectinib for RXDX-101

Financial news for RXDX dated on 2014-12-02: Ignyta Announces CLIA Certification Achieved By Its Diagnostic Laboratory

Financial news for RXDX dated on 2014-11-07: Ignyta Reports Q3 EPS of \$(0.55)

Financial news for RXDX dated on 2014-10-08: Shares of Ignyta Resume Trade Following Circuit Breaker, Now Down ~6%

Financial news for RXDX dated on 2014-10-01: Ignyta Secures \$31M Term Loan Facility From Silicon Valley Bank

Financial news for RXDX dated on 2014-09-28: Ignyta Presents Positive Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress

Financial news for RXDX dated on 2014-08-12: Ignyta Reports Q2 EPS of \$(0.28) vs \$(0.25) Est; Revenue of \$150.0K

Financial news for RXDX dated on 2014-08-11: Ignyta Names Adrian Senderowicz, M.D. as CMO

Financial news for RXDX dated on 2014-07-21: Ignyta Announces Initiation Of STARTRK-1 Global Phase I/II Clinical Trial Of RXDX-101

Financial news for RXDX dated on 2014-06-24: Ignyta to be Added to Russell Microcap Index

Financial news for RXDX dated on 2014-05-31: Ignyta Presents Promising Interim Data from RXDX-101 Phase I Clinical Trial at ASCO

Financial news for RXDX dated on 2014-05-30: Ignyta Announces Naming of Chacko as CFO, Hornby as COO

Financial news for RXDX dated on 2014-05-12: Ignyta Reports Q1 EPS of \$(0.28) vs \$(0.35) Est

Financial news for RXDX dated on 2014-05-02: Form 8-K from Ignyta Shows Co. Terminated Chief Medical Officer Sara Zaknoen

Financial news for RXDX dated on 2014-03-17: Ignyta Announces Underwriters' Full Exercise of Option to Purchase Additional Shares in Public Offering of Common Stock

Financial news for RXDX dated on 2014-03-13: Ignyta Prices 5.245M Share Offering at \$9.15/Share